Extending the continual reassessment method to accommodate step-up dosing in phase I trials

DOI10.1002/SIM.9487MaRDI QIDQ6628516zbMATH OpenFDO

Authors Thomas M. Braun, Francois Mercier

Publication date 29 October 2024

Published in Statistics in Medicine (Search for Journal in Brave)

Copyright license Creative Commons Attribution 4.0 International

Full work available at URL https://doi.org/10.1002/SIM.9487

zbMATH Keywords

adaptive clinical trialBayesian inferenceconditional probabilitydose escalationfractionated dosingup-titration

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Non-parametric optimal design in dose finding studies
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

This page was built for publication: Extending the continual reassessment method to accommodate step-up dosing in phase I trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6628516)